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cost—effectiveness of sequential adjuvant therapy vs. monother-
apies with aromatase inhibitors (AI) or tamoxifen in post-
menopausal women with Early-Stage breast cancer from the
Mexican health care payer’s perspective. METHODS: We used
a ten-year Markov analysis model to estimate costs and effec-
tiveness. Effectiveness measure was the % of patients free of
recurrence (local or distant). Transition probabilities were
obtained from international published literature. Comparators
were: tamoxifen 20 mg/day (ﬁve years); anastrozole 1 mg/day
(ﬁve years); letrozole 2.5 mg/day (ﬁve years) and the sequential
therapy with tamoxifen 20 mg/day (2.5-years) + exemestane 25
mg/day (ﬁve-years). Resource use estimations were performed
employing hospital records in an oncology hospital from the
Social Security Mexican Institute-IMSS in Mexico City (n = 104).
They included emergency, surgery, chemotherapy, outpatient and
inpatient services, drugs, oncology procedures, etc. Costs and
effectiveness measures were discounted 3% annually. One-way
and probabilistic sensitivity analyses were performed and accept-
ability curves were constructed. RESULTS: Sequential therapy
with tamoxifen followed by cross over to exemestane at 2.5-
years yielded 84.2% of patients free of recurrence in the ten-
years analysis followed of the two other AI monotherapies
(81.6%) and tamoxifen monotherapy (79.5%). The latter
showed the lower expected costs (US$23,968.3) followed by the
sequential therapy (US$29,077.3), anastrozole (US$30,615.2)
and letrozole (US$31,478.3). Sequential therapy was the option
most cost effective compared to AI monotherapies. Results were
robust to Monte Carlo second order sensitivity analysis. Accept-
ability curves showed the same results with a mean of 83.7% of
certainty. CONCLUSION: Sequential therapies should be con-
sidered as options more cost-effective compared to monothera-
pies. These results should be taken into account by Mexican
clinicians in the management of these patients.
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OBJECTIVES: To estimate cost-effectiveness of adjuvant
trastuzumab for one year following standard chemotherapy in
HER2-positive early breast cancer (EBC) versus standard therapy
alone (observation). METHODS: Markov model was developed
based on results of pivotal clinical study (HERA). The health
states included disease free survival, recurrence (local, contralat-
eral), distant metastases, cardiac adverse events and death. The
cohort simulation starts with 50-year-old patients who are con-
sidered disease free, i.e. have undergone surgery, chemo- and/or
radiotherapy. Effectiveness was measured in terms of QALY
gained. Population-based utilities were derived from published
literature. Yearly costs of each health state were established based
on the opinion of Polish experts from two oncology centers and
reported in PLN (1 EUR = 3.8 PLN in 2006). Direct medical costs
and outcomes were projected over patients’ lifetimes from a Polish
health care payer’s perspective, using 5% discount rate for both
or costs only. Probabilistic sensitivity analysis was performed.
RESULTS: The total lifetime costs/patient were estimated to be
198,294 PLN in trastuzumab and 62,812 PLN in no-trastuzumab
arm respectively. The main cost driver was the aquisition cost of
trastuzumab. The total QALYs generated with trastuzumab treat-
ment were 9.53 vs 7.5 for no trastuzumab treatment (discounted)
and 16.56 vs 11.9 QALY (without discounting) respectively. This
results in ICER for trastuzumab of 66,746 PLN/QALY (dis-
counted) and 30,769 PLN/QALY (with only costs discounted).
Probabilistic sensitivity analysis showed that for 50% simulations
the ICER remained below 60,000 PLN/QALY and for 97.5%—
below 88,624 PLN/QALY. CONCLUSION: The use of trast-
uzumab in EBC improves QALYs compared to observation alone.
Considering the suggested threshold for cost-effectiveness, 
calculated on the basis of one-year haemodialysis treatment costs
(60,000–74,700 PLN), adjuvant therapy with trastuzumab
appears to be cost-effective treatment for patients with HER2-
positive EBC in Poland.
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OBJECTIVES: Anastrozole primary adjuvant therapy compared
to tamoxifen signiﬁcantly improves disease free survival (DFS)
and time to recurrence (TTR) and signiﬁcantly reduces distant
metastases and contralateral breast cancers in PM women with
hormone-receptor positive early BC. METHODS: We developed
a Markov model describing the clinical history of PM women
with early BC that projected improvements in lifetime life years
gained (LYG), long-term costs, and cost-effectiveness of the
adjuvant treatment with anastrozole compared to that with
tamoxifen. The base case was a 64-year-old PM women with
hormone-receptor positive BC submitted to mastectomy and
without metastases. Transition probabilities came from the
ATAC study and other major studies from the medical literature.
The local management and costs of each health state was based
on a Delphi panel according to the private health care perspec-
tive. Outcomes were discounted at 3% annually. Sensitivity
analyses and a second order Monte Carlo simulation were per-
formed. RESULTS: The lifetime horizon analysis showed: Anas-
trozole in comparison to tamoxifen increased life expectancy
(LY) in 0,55 year; the incremental cost per LYG was
R$27.693,36; the tamoxifen group expenses in comparison to
the anastrozole group in recurrence states (loco-regional disease
and metastasis) and with adverse events were respectively 17%
and 16% higher. CONCLUSION: Improvements in DFS and
TTR with primary adjuvant anastrozole in postmenopausal
women with operable hormone-receptor positive breast cancer
improves patient outcomes in terms of LYG with an acceptable
cost-effectiveness ratio in Brazil.
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OBJECTIVES: While early studies showed the efﬁcacy of gran-
ulocyte colony-stimulating factor (G-CSF) in preventing febrile
